Insulinotropic Hormone Secretion Peptide Fusion Protein(Wuxi Hebang Biotechnology Co. Ltd.)

Main purpose: Evaluate the safety and tolerability of HB1085 after multiple continuous administration in healthy subjects; Evaluate the pharmacokinetic characteristics of different doses of HB1085 after multiple administration in healthy subjects. Secondary purpose: Preliminary evaluation of the pharmacodynamic characteristics of different doses of HB1085 after multiple administration in healthy subjects; Provide a basis for dose selection for subsequent clinical studies of HB1085; Evaluate the immunogenicity of HB1085 after multiple administration in healthy subjects at different doses.

Primary objective: To evaluate the safety and tolerability of a single subcutaneous administration of insulin secretion-promoting peptide fusion protein (HB1085) in healthy Chinese volunteers by observing adverse events and serious adverse events. Secondary objective: To evaluate the pharmacokinetic characteristics of insulin secretion-promoting peptide fusion protein by monitoring the concentration of insulin secretion-promoting peptide fusion protein after subcutaneous administration of HB1085 in healthy volunteers.